Inhibition of Tumor Growth by Direct Intratumoral Gene Transfer of Herpes Simplex Virus Thymidine Kinase Gene with DNA–Liposome Complexes
- 20 January 1996
- journal article
- Published by Mary Ann Liebert Inc in Human Gene Therapy
- Vol. 7 (2), 223-230
- https://doi.org/10.1089/hum.1996.7.2-223
Abstract
To establish the expression of the herpes simplex virus thymidine kinase (HSV-TK) gene in tumor cells, we analyzed the promoter function of the SV40 promoter and the nucleotide sequence (CACGTG) to which Myc-Max heterodimers (Myc/Max) were capable of binding in four kinds of cell lines: COLO320 DM, A-431, KF, and Nakajima. When luciferase reporter plasmid under the control of SV40 promoter was transfected into tumor cells in vitro, a high level of luciferase activity was observed in all kinds of cell lines. However, by transfection of the luciferase gene promoted by the Myc/Max binding sequence, accelerated luciferase expression was observed in COLO320 DM and A-431 cells with high expression of c-myc, but not in KF and Nakajima cells, which showed low expression of c-myc. The repeated transfection of the liposome-conjugated HSV-TK gene regulated by the SV40 promoter and cultivation in 100 micrograms/ml of aciclovir for 5 days in vitro demonstrated growth inhibition for all four kinds of cell lines. However, cell toxicity was observed only in COLO320 DM and A-431 cells when the HSV-TK gene promoted by the Myc/Max binding sequence was introduced. (The survival rate to 100 micrograms/ml of aciclovir concentration in COLO320 DM, A-431, KF, and Nakajima cells was 59%, 53%, 74%, and 79%, respectively.) In vivo direct injection of the liposome-conjugated HSV-TK gene regulated by the SV40 promoter into established tumors and aciclovir administration for 10 days into the mice resulted in significant tumor volume reduction in three tested tumor cells. However, injection of the HSV-TK gene promoted by the Myc/Max binding sequence and aciclovir administration into mice could achieve significant tumor regression only in COLO320 DM and A-431 cells. These results suggest that gene therapy using the HSV-TK gene promoted by the Myc/Max binding sequence can be an attractive approach for treatment against tumor cells expressing high levels of c-myc.Keywords
This publication has 21 references indexed in Scilit:
- Combination gene therapy for liver metastasis of colon carcinoma in vivo.Proceedings of the National Academy of Sciences, 1995
- In VitroEvidence That Metabolic Cooperation Is Responsible for the Bystander Effect Observed with HSVtkRetroviral Gene TherapyHuman Gene Therapy, 1993
- In Vivo Gene Transfer with Retroviral Vector-Producer Cells for Treatment of Experimental Brain TumorsScience, 1992
- Gene therapy for cancerThe Lancet, 1992
- A novel cationic liposome reagent for efficient transfection of mammalian cellsBiochemical and Biophysical Research Communications, 1991
- Efficient gene transfer into mammalian primary endocrine cells with lipopolyamine-coated DNA.Proceedings of the National Academy of Sciences, 1989
- Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure.Proceedings of the National Academy of Sciences, 1987
- The human c-myc oncogene: Structural consequences of translocation into the igh locus in Burkitt lymphomaCell, 1983
- CELLULAR ONCOGENES AND RETROVIRUSESAnnual Review of Biochemistry, 1983
- In Vitro Cultivation of Human Tumors: Establishment of Cell Lines Derived From a Series of Solid Tumors2JNCI Journal of the National Cancer Institute, 1973